KR20030091952A - 선택적인 암 치료용의 특이적 인간 항체 - Google Patents
선택적인 암 치료용의 특이적 인간 항체 Download PDFInfo
- Publication number
- KR20030091952A KR20030091952A KR10-2003-7008885A KR20037008885A KR20030091952A KR 20030091952 A KR20030091952 A KR 20030091952A KR 20037008885 A KR20037008885 A KR 20037008885A KR 20030091952 A KR20030091952 A KR 20030091952A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- peptide
- seq
- cell
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75118100A | 2000-12-29 | 2000-12-29 | |
US09/751,181 | 2000-12-29 | ||
PCT/US2001/049440 WO2002059264A2 (en) | 2000-12-29 | 2001-12-31 | Specific human antibodies for selective cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030091952A true KR20030091952A (ko) | 2003-12-03 |
Family
ID=25020844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-7008885A KR20030091952A (ko) | 2000-12-29 | 2001-12-31 | 선택적인 암 치료용의 특이적 인간 항체 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1353937A4 (zh) |
JP (1) | JP2004524023A (zh) |
KR (1) | KR20030091952A (zh) |
CN (1) | CN100374456C (zh) |
AU (1) | AU2002246737B2 (zh) |
BR (1) | BR0116763A (zh) |
CA (1) | CA2433227A1 (zh) |
CZ (1) | CZ20031983A3 (zh) |
HU (1) | HUP0400775A2 (zh) |
IL (1) | IL156690A0 (zh) |
MX (1) | MXPA03005944A (zh) |
NZ (1) | NZ527173A (zh) |
PL (1) | PL365758A1 (zh) |
RU (1) | RU2316564C2 (zh) |
WO (1) | WO2002059264A2 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003279657A1 (en) * | 2002-07-01 | 2004-01-19 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
RU2006102571A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Специфические антитела человека |
EP1877444A2 (en) | 2005-04-26 | 2008-01-16 | Pfizer, Inc. | P-cadherin antibodies |
EP2373343B1 (en) * | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
MY161679A (en) * | 2010-07-09 | 2017-05-15 | Affibody Ab | Polypeptides |
CN101948534B (zh) * | 2010-08-19 | 2014-05-28 | 中国科学院生物物理研究所 | 一种筛选抗体的方法 |
GB201310544D0 (en) * | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
US9695234B2 (en) * | 2014-10-23 | 2017-07-04 | Singh Molecular Medicine, Llc | Single domain antibodies directed against STAT3 |
WO2016100533A2 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
CN108290940B (zh) * | 2015-10-01 | 2021-12-07 | 圣拉斐尔医院有限公司 | Tcr及其用途 |
WO2017087789A1 (en) * | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
CR20220408A (es) * | 2016-09-14 | 2022-10-20 | Teneobio Inc | ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198) |
EP4244251A1 (en) * | 2020-11-13 | 2023-09-20 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
US6132730A (en) * | 1997-01-22 | 2000-10-17 | Board Of Regents, The University Of Texas System | Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment |
-
2001
- 2001-12-31 PL PL01365758A patent/PL365758A1/xx unknown
- 2001-12-31 NZ NZ527173A patent/NZ527173A/xx unknown
- 2001-12-31 IL IL15669001A patent/IL156690A0/xx unknown
- 2001-12-31 CZ CZ20031983A patent/CZ20031983A3/cs unknown
- 2001-12-31 WO PCT/US2001/049440 patent/WO2002059264A2/en active IP Right Grant
- 2001-12-31 EP EP01994329A patent/EP1353937A4/en not_active Withdrawn
- 2001-12-31 MX MXPA03005944A patent/MXPA03005944A/es not_active Application Discontinuation
- 2001-12-31 KR KR10-2003-7008885A patent/KR20030091952A/ko not_active Application Discontinuation
- 2001-12-31 AU AU2002246737A patent/AU2002246737B2/en not_active Ceased
- 2001-12-31 CA CA002433227A patent/CA2433227A1/en not_active Abandoned
- 2001-12-31 HU HU0400775A patent/HUP0400775A2/hu unknown
- 2001-12-31 JP JP2002559551A patent/JP2004524023A/ja active Pending
- 2001-12-31 RU RU2003123100/13A patent/RU2316564C2/ru not_active IP Right Cessation
- 2001-12-31 BR BR0116763-4A patent/BR0116763A/pt not_active IP Right Cessation
- 2001-12-31 CN CNB018228852A patent/CN100374456C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2002246737B2 (en) | 2007-03-01 |
CN100374456C (zh) | 2008-03-12 |
EP1353937A2 (en) | 2003-10-22 |
WO2002059264A3 (en) | 2003-03-06 |
EP1353937A4 (en) | 2005-04-13 |
MXPA03005944A (es) | 2005-04-29 |
CA2433227A1 (en) | 2002-08-01 |
PL365758A1 (en) | 2005-01-10 |
CZ20031983A3 (cs) | 2005-07-13 |
BR0116763A (pt) | 2004-03-09 |
CN1551886A (zh) | 2004-12-01 |
NZ527173A (en) | 2006-03-31 |
WO2002059264A2 (en) | 2002-08-01 |
HUP0400775A2 (en) | 2007-05-02 |
IL156690A0 (en) | 2004-01-04 |
JP2004524023A (ja) | 2004-08-12 |
RU2003123100A (ru) | 2005-03-10 |
RU2316564C2 (ru) | 2008-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070149768A1 (en) | Specific human antibodies for selective cancer therapy | |
US20040002450A1 (en) | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040001822A1 (en) | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20090220486A1 (en) | Antibodies and uses thereof | |
EP1268800A2 (en) | Mucin-1 specific binding members and methods of use thereof | |
AU2001249760A1 (en) | Mucin-1 specific binding members and methods of use thereof | |
US20040001839A1 (en) | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
AU2002246737B2 (en) | Specific human antibodies for selective cancer therapy | |
AU2002246737A1 (en) | Specific human antibodies for selective cancer therapy | |
MXPA03005945A (es) | Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos. | |
JP2005503756A5 (zh) | ||
US20040202665A1 (en) | Compositions and methods for therapeutic treatment | |
CA2491363A1 (en) | Antibodies and uses thereof | |
KR20050059001A (ko) | 치료적 처리를 위한 조성물 및 방법 | |
JP2007528711A (ja) | 抗体及びその使用 | |
US20040208877A1 (en) | Antibodies and uses thereof | |
KR102698752B1 (ko) | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 | |
KR20240148849A (ko) | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 | |
AU2002246738A1 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |